New Jersey is currently home to 1657 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Brunswick, Hackensack, Newark and Morristown. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis
NCT02205762
Recruiting
The LCH-IV is an international, multicenter, prospective clinical study for pediatric Langerhans Cell Histiocytosis LCH (age \< 18 years).
Gender:
ALL
Ages:
18 years and below
Trial Updated:
03/21/2023
Locations: Hackensack University Medical Center, Hackensack, New Jersey
Conditions: Langerhans Cell Histiocytosis
Register for Updates
Follow-up With Preimplantation Genetic Testing Patients
NCT04477863
Recruiting
The main purpose of this study is to perform longitudinal evaluations of clinical outcomes and personal perspectives following utilization of preimplantation genetic testing (PGT). Patients indicating willingness to participate in research during informed consent to perform PGT will be eligible for inclusion. A licensed genetic counselor will conduct a recorded interview.
Gender:
ALL
Ages:
All
Trial Updated:
02/21/2023
Locations: Genomic Prediction Clinical Laboratory, North Brunswick, New Jersey
Conditions: Infertility, Genetic Disease, IVF
Register for Updates
Proton and Photon Consortium Registry (PPCR): A Multi Center Registry of Pediatric Patients Treated With Radiation Therapy
NCT01696721
Recruiting
In previous studies, Proton Beam Radiation Therapy (PBRT) has been found to show better results in treating patients with cancer, both because there is better control of where in the body the radiation is directed and because it is associated with less severe long term side effects. However, there is limited published data demonstrating these results. The goal of the Proton and Photon Consortium Registry (PPCR) is to enroll children treated with radiation in order to describe the population that... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
01/05/2023
Locations: ProCure Proton Therapy Center- New Jersey, Somerset, New Jersey
Conditions: Pediatric Patients Treated With Radiation Therapy
Register for Updates
Accelerated Corneal Collagen Crosslinking for Keratoconus and Ectasia Using Pulse or Continuous UV-A Light
NCT05027295
Recruiting
Corneal collagen crosslinking has been demonstrated as an effective method of reducing progression of both keratoconus and post-refractive corneal ectasia, as well as decreasing the steepness of the cornea in these pathologies. Performing an accelerated CXL procedure with pulsed UVA light may increase the oxygenation of the cornea, which may improve the crosslinking efficacy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/30/2022
Locations: Cornea and Laser Eye Institute, Hersh Vision Group, Teaneck, New Jersey
Conditions: Keratoconus, Corneal Ectasia
Register for Updates
Transepithelial (Epi-on) Corneal Collagen Crosslinking to Treat Keratoconus and Corneal Ectasia
NCT04905108
Recruiting
Corneal collagen crosslinking (CXL) has been demonstrated as an effective method of reducing progression of both keratoconus and corneal ectasia after surgery, as well as possibly decreasing the steepness of the cornea in these pathologies. Transepithelial crosslinking in which the epithelium is not removed has been proposed to offer a number of advantages over traditional crosslinking including an increased safety profile by reducing the risk for infection and scarring, faster visual recovery a... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
12/30/2022
Locations: Cornea and Laser Eye Institute, Hersh Vision Group, Teaneck, New Jersey
Conditions: Keratoconus, Corneal Ectasia
Register for Updates
Corneal Collagen Crosslinking for Keratoconus and Ectasia Using Riboflavin/Dextran or Riboflavin/Methylcellulose
NCT04897503
Recruiting
This study is being conducted to evaluate the safety and efficacy of isotonic riboflavin for corneal collagen crosslinking for keratoconus and corneal ectasia. will determine the safety and efficacy of corneal collagen crosslinking (CXL) performed with two different riboflavin formulations for reducing corneal curvature.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
12/30/2022
Locations: Cornea and Laser Eye Institue - Hersh Vision Group, Teaneck, New Jersey
Conditions: Keratoconus, Corneal Ectasia
Register for Updates
Exercise Dose and Metformin for Vascular Health in Adults With Metabolic Syndrome
NCT04817787
Recruiting
Arterial disease is the leading cause of morbidity/mortality in Metabolic syndrome (MetS). This occurs early as evidenced by arterial dysfunction that, in turn, raises blood pressure and glucose. Health organizations recommend exercise in an intensity based manner to promote cardiovascular adaptation and prevent disease. Metformin is a common anti-diabetes medication that reduces future type 2 diabetes and cardiovascular risk. However, the optimal exercise dose to be combined with metformin for... Read More
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
12/23/2022
Locations: Loree Gymnasium, New Brunswick, New Jersey
Conditions: Metabolic Syndrome, Insulin Sensitivity, Vascular Stiffness
Register for Updates
Comparison of Two Group Wellness Interventions for Individuals With Neurologic Conditions and Their Support Persons
NCT05048966
Recruiting
Approximately 5.3 million people live with a long-term disability resulting from a traumatic brain injury (TBI) and between 5-8% of those older than 60 suffer from Alzheimer's disease or other forms of dementia (ADRD). Consequences of these conditions can result in dramatic and persistent changes in functioning, impacting not only the patients, but also loved ones who become informal support persons. Many existing services help the family in the moment, but do not address long-term wellness. Thu... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/14/2022
Locations: Kessler Foundation, East Hanover, New Jersey
Conditions: Traumatic Brain Injury, Mild Traumatic Brain Injury, Alzheimer's Disease, Brain Injury Traumatic Moderate, Brain Injury Traumatic Severe, Dementia
Register for Updates
2-level Cervical Disc Replacement Comparing Prodisc C SK & Vivo to Mobi-C
NCT04012996
Recruiting
A multi-center, prospective, randomized, controlled comparison of the prodisc C SK and prodisc C Vivo to the control, a similar, legally marketed total disc replacement device in subjects with symptomatic cervical disc disease (SCDD).
Gender:
ALL
Ages:
Between 18 years and 69 years
Trial Updated:
10/27/2022
Locations: University Spine Center, Wayne, New Jersey
Conditions: Symptomatic Cervical Disc Disease
Register for Updates
REFINE Study: A Study In a Novel Interspinous Fusion Device In Subjects With Low Back Pain
NCT05504499
Recruiting
The purpose of this study is to evaluate the effectiveness and safety of the use of Aurora Spine ZIP™ MIS Interspinous Fusion System and bone graft material in fusion in patients with chronic low back pain that present with degenerative disc disease with concurrent neurogenic claudication.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/16/2022
Locations: The Pain Management Center, Voorhees, New Jersey
Conditions: Lumbar Spinal Stenosis
Register for Updates
Evaluation of the FELLAS Responsible Fatherhood Project
NCT05412641
Recruiting
The Partnership for Maternal and Child Health of Northern New Jersey, Inc. (PMCH) is implementing a fatherhood project with the goal of strengthening father-child engagement, improving economic stability, and improving healthy marriage/relationship skills among participants. FELLAS serves community-based fathers 18 years of age or older who reside in Essex County, New Jersey and have at least one child under the age of 24. The program model has three components: to improve responsible parenting... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/07/2022
Locations: Partnership for Maternal & Child Health of Northern New Jersey, Newark, New Jersey
Conditions: Responsible Fatherhood
Register for Updates
KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF
NCT04640532
Recruiting
This study evaluates KRT-232 in Combination With TL-895 for the Treatment of Relapsed or Refractory Myelofibrosis and KRT-232 for the Treatment of JAK Inhibitor Intolerant Myelofibrosis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2022
Locations: Columbia University Medical Center, Fort Lee, New Jersey
Conditions: Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis, Primary Myelofibrosis
Register for Updates